William Blair Starts Viridian Therapeutic (VRDN) at Outperform

William Blair analyst Lachlan Hanbury-Brown initiates coverage on Viridian Therapeutic (NASDAQ: VRDN) with a Outperform rating.

The analyst comments "We are initiating coverage of Viridian with an Outperform rating and $47 fair value estimate, based on our belief that the company’s anti-IGF-1R franchise represents a meaningful advance compared to Tepezza for the treatment of thyroid eye disease (TED). While we acknowledge that growth in the U.S. TED market has plateaued in recent years, we believe that new therapies offering a more convenient administration, cleaner picture of the adverse event profile of IGF-1R inhibition, and diplopia benefit in chronic disease have potential to grow the market. In particular, while we believe veligrotug has important advantages over Tepezza that could drive share capture and modest market expansion following a potential mid-2026 approval, we believe the bigger value driver is the subcutaneously administered VRDN-003, for which top-line Phase III data are expected in the first and second quarters of 2026."

For an analyst ratings summary and ratings history on Viridian Therapeutic click here. For more ratings news on Viridian Therapeutic click here.

Shares of Viridian Therapeutic closed at $30.43 yesterday.

You May Also Be Interested In

• UGI shares spike on reported KKR bid for the company
• IP Strategy Holdings (IPST) halted, news pending
• Marvell (MRVL) PT Raised to $225 at TD Cowen